• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Baricitinib is superior to placebo for treatment of alopecia areata

byDavid XiangandHarsh Shah
April 22, 2022
in Chronic Disease, Dermatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Oral baricitinib is superior to placebo regarding hair regrowth at 36 weeks.

2. Oral baricitinib led to lower severity of alopecia areata compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Alopecia areata is an autoimmune disorder that causes nonscarring hair loss that can affect any hair-bearing site, which can cause emotional and psychosocial distress. Extensive alopecia areata is unlikely to be remit without treatment, which currently consists of glucocorticoids, other immunosuppressive agents, and contact immunotherapy, which are not approved by the FDA. Baricitinib, a reversible JAK1, and JAK2 inhibitor, has been posited to reverse hair loss in patients with alopecia areata in previous reports. However, there is a gap in knowledge as to understanding Baricitinib’s effectiveness in causing hair regrowth among patients with alopecia areata. This study found that once-daily oral Baricitinib was reported to be superior to placebo regarding hair regrowth after 36 weeks. This study was limited by factors such as some assessments being performed remotely due to the Covid-19 pandemic, as well as a selective study population since patients with a previous inadequate response to oral JAK inhibitors and patients with an episode lasting at least 8 years without any hair regrowth were excluded from the study. Nevertheless, these study’s findings are significant, as they demonstrate that Baricitinib was superior to placebo with respect to hair regrowth in patients with alopecia areata.

Click to read the study in NEJM

Relevant Reading: Genetic Susceptibility to Alopecia

In-Depth [randomized control trial]: This randomized control trial studied 1200 patients with severe alopecia areata. Patients who had a Severity of Alopecia Tool (SALT) score of 50 or higher, with 0 representing no scalp hair loss and 100 representing complete scalp hair loss, and a current episode of alopecia areata lasting more than 6 months to less than 8 years without spontaneous improvement during the previous 6 months were eligible for the study. Patients who had a diffuse pattern of alopecia areata, or had been treated with agents such as topical glucocorticoids within 1 week before randomization, systemic glucocorticoids within 8 weeks before randomization, and JAK inhibitors within 4-8 weeks before randomization, or had an inadequate response to oral JAK inhibitors, were excluded from the study. The primary outcome measured was a SALT score of 20 or less at week 36, which has been identified as a meaningful treatment outcome for patients with severe alopecia areata. Outcomes in the primary analysis were assessed via graphical testing schemes and efficacy analysis with the use of logistic regression and analysis of covariance. Based on the analysis and two trials (BRAVE-AA1 and BRAVE-AA2) conducted, 38.8% of patients receiving daily 4mg baricitinib, 22.8% of patients receiving daily 2mg baricitinib, and 6.2% of patients receiving placebo had a SALT score of 20 or less at week 36 in the BRAVE-AA1 trial. In the BRAVE-AA2 trial, 35.9% of patients receiving 4mg baricitinib, 19.4% of patients receiving daily 2mg baricitinib, and 3.3% of patients receiving placebo had a SALT score of 20 or less at week 36. The difference between 4mg baricitinib and placebo was 32.6% (95% Confidence Interval [CI], 25.6 to 39.50 and the difference between 2mg baricitinib and placebo was 16.6% (95% CI, 9.5 to 23.8) in the BRAVE-AA1 trial. In the BRAVE-AA2 trial, the difference between 4mg baricitinib and placebo was 32.6% (25.6 to 39.6) and 16.1% (95% CI, 9.1 to 23.2) between 2mg baricitinib and placebo. Overall, this study demonstrated that once-daily oral baricitinib was superior to placebo with respect to hair regrowth, though longer trials are necessary to determine the efficacy and safety of baricitinib for alopecia areata, with trial lengths of 200 weeks recommended.

RELATED REPORTS

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alopecia areatabaricitinibhairhair lossJAK inhibitor
Previous Post

Vaccination leads to a small absolute risk for shoulder conditions

Next Post

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

August 11, 2022
#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia
StudyGraphics

#VisualAbstract: Dutasteride 0.5mg daily has the highest probability of being the most efficacious treatment for male androgenetic alopecia

February 10, 2022
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
StudyGraphics

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

December 16, 2021
#VisualAbstract Persistent chemotherapy-induced alopecia was more severe with the use of taxanes in breast cancer survivors
StudyGraphics

#VisualAbstract Persistent chemotherapy-induced alopecia was more severe with the use of taxanes in breast cancer survivors

October 7, 2021
Next Post
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Oral tebipenem pivoxil hydrobromide is effective in treatment of complicated urinary tract infection

Patient Basics: Stroke Overview

Endovascular therapy for large ischemic strokes provides better functional outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options